JP2010535014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535014A5 JP2010535014A5 JP2010504318A JP2010504318A JP2010535014A5 JP 2010535014 A5 JP2010535014 A5 JP 2010535014A5 JP 2010504318 A JP2010504318 A JP 2010504318A JP 2010504318 A JP2010504318 A JP 2010504318A JP 2010535014 A5 JP2010535014 A5 JP 2010535014A5
- Authority
- JP
- Japan
- Prior art keywords
- ly6k
- cancer
- level
- protein
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001065550 Homo sapiens Lymphocyte antigen 6K Proteins 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 74
- 102100032129 Lymphocyte antigen 6K Human genes 0.000 claims description 63
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 33
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 32
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 32
- 201000004101 esophageal cancer Diseases 0.000 claims description 32
- 239000000523 sample Substances 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims description 17
- 238000001514 detection method Methods 0.000 claims description 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 13
- 201000005202 lung cancer Diseases 0.000 claims description 13
- 208000020816 lung neoplasm Diseases 0.000 claims description 13
- 239000012472 biological sample Substances 0.000 claims description 12
- 238000003018 immunoassay Methods 0.000 claims description 12
- 230000004071 biological effect Effects 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 239000013641 positive control Substances 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 238000004393 prognosis Methods 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 108010036226 antigen CYFRA21.1 Proteins 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 238000009396 hybridization Methods 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 238000010837 poor prognosis Methods 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 108091028664 Ribonucleotide Proteins 0.000 description 11
- 239000002336 ribonucleotide Substances 0.000 description 11
- 125000002652 ribonucleotide group Chemical group 0.000 description 11
- 108020004459 Small interfering RNA Proteins 0.000 description 10
- 239000004055 small Interfering RNA Substances 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 9
- 108091081021 Sense strand Proteins 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 239000012634 fragment Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95283007P | 2007-07-30 | 2007-07-30 | |
| PCT/JP2007/001281 WO2009016691A1 (en) | 2007-07-30 | 2007-11-21 | Cancer associated gene ly6k |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010535014A JP2010535014A (ja) | 2010-11-18 |
| JP2010535014A5 true JP2010535014A5 (enExample) | 2011-01-13 |
Family
ID=39267387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010504318A Pending JP2010535014A (ja) | 2007-07-30 | 2007-11-21 | 癌関連遺伝子ｌｙ６ｋ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20100291091A1 (enExample) |
| EP (1) | EP2185732A1 (enExample) |
| JP (1) | JP2010535014A (enExample) |
| WO (1) | WO2009016691A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1853703B1 (en) * | 2005-02-25 | 2011-04-13 | Oncotherapy Science, Inc. | Peptide vaccines for lung cancers expressing ttk polypeptides |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| TWI580431B (zh) | 2008-08-19 | 2017-05-01 | 腫瘤療法 科學股份有限公司 | Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗 |
| US9644010B2 (en) | 2012-07-10 | 2017-05-09 | Oncotherapy Science, Inc. | LY6K epitope peptides for TH1 cells and vaccines containing the same |
| JP6455935B2 (ja) * | 2013-12-27 | 2019-01-23 | 国立大学法人高知大学 | 食道がんのマーカーおよびその利用 |
| SG10201900835XA (en) | 2014-08-04 | 2019-03-28 | Oncotherapy Science Inc | Urlc10-derived peptide and vaccine containing same |
| CN108893446A (zh) * | 2018-06-08 | 2018-11-27 | 河北医科大学第医院 | 男性食管癌细胞系及其应用 |
| CN108828229B (zh) * | 2018-06-15 | 2021-03-16 | 深圳华大生命科学研究院 | 食管癌肿瘤标志物组合及其应用 |
| CN119923407A (zh) * | 2022-01-14 | 2025-05-02 | 新加坡国立大学 | 靶向人淋巴细胞抗原6家族成员k（ly6k）的三种抗体候选物的抗体序列 |
| TW202412744A (zh) * | 2022-06-07 | 2024-04-01 | 瑞士商意梭凱普公司 | 包括應用在食道黏膜之藥劑的藥物遞送系統及其應用 |
| CN120842364A (zh) * | 2025-07-25 | 2025-10-28 | 广州医科大学附属第一医院（广州呼吸中心） | 肿瘤细胞高表达抗原ly6k的抗原表位肽及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008439A1 (en) * | 1996-08-25 | 1998-03-05 | Sensar, Inc. | Apparatus for the iris acquiring images |
| EP1497454A2 (en) * | 2001-11-13 | 2005-01-19 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US20030232350A1 (en) * | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| TW200413725A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| KR20060120652A (ko) * | 2003-10-07 | 2006-11-27 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 난소암의 확인, 평가, 예방 및 치료를 위한 핵산 분자 및단백질 |
| EP2295601A1 (en) * | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| EP1853703B1 (en) * | 2005-02-25 | 2011-04-13 | Oncotherapy Science, Inc. | Peptide vaccines for lung cancers expressing ttk polypeptides |
| US20090175884A1 (en) * | 2007-08-30 | 2009-07-09 | Cashman Neil Roy | Misfolded proteins in cancer treatment and diagnosis |
| TW201008574A (en) * | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
-
2007
- 2007-11-21 WO PCT/JP2007/001281 patent/WO2009016691A1/en not_active Ceased
- 2007-11-21 JP JP2010504318A patent/JP2010535014A/ja active Pending
- 2007-11-21 US US12/671,447 patent/US20100291091A1/en not_active Abandoned
- 2007-11-21 EP EP07828058A patent/EP2185732A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535014A5 (enExample) | ||
| Liu et al. | Combination of plasma microRNAs with serum CA19‐9 for early detection of pancreatic cancer | |
| JP2006500949A5 (enExample) | ||
| Rahbari et al. | Identification of differentially expressed microRNA in parathyroid tumors | |
| CN102333887B (zh) | 用于检测gi癌转移的方法 | |
| JP2009502116A5 (enExample) | ||
| JP2006500948A5 (enExample) | ||
| US20160146818A1 (en) | Bladder cancer detection composition, kit, and associated methods | |
| JP2007506426A5 (enExample) | ||
| KR20160045547A (ko) | 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법 | |
| CN106662543B (zh) | 肺癌患者中的非侵入性基因突变检测 | |
| JP2012511305A5 (enExample) | ||
| BRPI0707642A2 (pt) | taxas de expressço de gene de urina para detecÇço de cÂncer | |
| JP2011526487A (ja) | 乳癌のゲノムフィンガープリント | |
| KR20180082328A (ko) | 전립선 암 예측 방법 | |
| BR112013011875A2 (pt) | Marcador para detecção de câncer de bexiga e/ou condições inflamatórias da bexiga | |
| EP3548631B1 (en) | Risk scores based on human phosphodiesterase 4d variant 7 expression | |
| Weber et al. | Extensive screening of microRNA populations identifies hsa-miR-375 and hsa-miR-133a-3p as selective markers for human rectal and colon cancer | |
| Shi et al. | Serum miR-629 is a novel molecular marker for diagnosis and the prognosis of pancreatic cancer. | |
| KR101594980B1 (ko) | 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법 | |
| ES2528672B1 (es) | Neurofilina-1 (NRP-1) urinaria como marcador pronóstico de nefritis y nefritis lúpica | |
| JP2006503575A5 (enExample) | ||
| KR20240157611A (ko) | 전이성 유방암의 항암제 치료 반응성 및 예후 예측용 신규한 바이오마커 및 이의 용도 | |
| JP2010501162A5 (enExample) | ||
| CN114746551A (zh) | 大肠癌诊断用标志物、辅助大肠癌的诊断的方法、收集数据以用于大肠癌诊断的方法、大肠癌的诊断试剂盒、大肠癌治疗药物、大肠癌的治疗方法、大肠癌的诊断方法 |